Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gentuximab Phase Ia in Metastatic Solid Tumors
NCT03313219Phase 1Unknown
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Oct 2017
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gentuximab in metastatic solid tumor, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoints: Dose-limiting toxicities up to 7 weeks, Maximum Concentration (Cmax) in single dose and 3 more. Status: unknown.
02
Drugs
gentuximab
03
Conditions
metastatic solid tumor
Beyond the preview
Go deeper on NCT03313219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03313219.